Trial reportIntensive care medicine2019
A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial.
Trial report in Intensive care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- The efficacy and safety of prokinetics in critically ill adults receiving gastric feeding tubes: A systematic review and meta-analysis.PloS one · 2021Pooled it
- The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review.Frontiers in psychiatry · 2020Pooled it
- Mosapride versus Metoclopramide in Critically Ill Patients with Enteral Feeding Intolerance: A Randomized, Double-Blinded Comparison.Drug design, development and therapy · 2026Trial
- The efficacy and safety of itopride in feeding intolerance of critically ill patients receiving enteral nutrition: a randomized, double-blind study.BMC gastroenterology · 2021Trial
- Prevalence, risk factors, and clinical consequence of enteral feeding intolerance in elderly patients with traumatic brain injury: a two-center study.European journal of clinical nutrition · 2026Article
- Addressing metabolic demands during veno-venous extracorporeal life support: A narrative review.JPEN. Journal of parenteral and enteral nutrition · 2026Review
- Development and validation of an interpretable machine learning model for predicting enteral nutrition-associated diarrhea in ICU patients: a multicenter study.Frontiers in nutrition · 2026Article
- Analysis of outcome indicators in clinical trials related to feeding intolerance in ICU patients receiving enteral nutrition feeding.Frontiers in nutrition · 2025Article
- Comparison of enteral prucaloprideFrontiers in pharmacology · 2024Article
- Prediction of prokinetic agents in critically ill patients with feeding intolerance: a prospective observational clinical study.Frontiers in nutrition · 2023Article
- Development of a prediction model for enteral feeding intolerance in intensive care unit patients: A prospective cohort study.World journal of gastrointestinal surgery · 2022Article
- Article
- Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor.Journal of medicinal chemistry · 2022Review
- Association between Domperidone Administered via Feeding Tube and Feeding Success in Critically Ill Patients with Enteral Feeding Intolerance.Journal of personalized medicine · 2021Article
- An examination of gastrointestinal absorption using the acetaminophen absorption test in critically ill patients with COVID-19: A retrospective cohort study.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2021Observational
- Review
- Focus on gastrointestinal system in critically ill patients.Intensive care medicine · 2020Article
- [Nutritional support for critically ill patients suffering from SARS-CoV-2 infection].Le praticien en anesthesie reanimation · 2020Review
- When and how to manage enteral feeding intolerance?Intensive care medicine · 2019Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 11 institutions in 4 countries.
Funding
Abstract
purposeEnteral feeding intolerance (EFI) is a frequent problem in the intensive care unit (ICU), but current prokinetic agents have uncertain efficacy and safety profiles. The current study compared the efficacy and safety of ulimorelin, a ghrelin agonist, with metoclopramide in the treatment of EFI.
methodsOne hundred twenty ICU patients were randomized 1:1 to ulimorelin or metoclopramide for 5 days. EFI was diagnosed by a gastric residual volume (GRV) ≥ 500 ml. A volume-based feeding protocol was employed, and enteral formulas were standardized. The primary end point was the percentage daily protein prescription (%DPP) received by patients over 5 days of treatment. Secondary end points included feeding success, defined as 80% DPP; gastric emptying, assessed by paracetamol absorption; incidences of recurrent intolerance (GRV ≥ 500 ml); vomiting or regurgitation; aspiration, defined by positive tracheal aspirates for pepsin; and pulmonary infection.
resultsOne hundred twenty patients were randomized and received the study drug (ulimorelin 62, metoclopramide 58). Mean APACHE II and SOFA scores were 21.6 and 8.6, and 63.3% of patients had medical reasons for ICU admission. Ulimorelin and metoclopramide resulted in comparable %DPPs over 5 days of treatment (median [Q1, Q3]: 82.9% [38.4%, 100.2%] and 82.3% [65.6%, 100.2%], respectively, p = 0.49). Five-day rates of feeding success were 67.7% and 70.6% when terminations unrelated to feeding were excluded, and there were no differences in any secondary outcomes or adverse events between the two groups.
conclusionsBoth prokinetic agents achieved similar rates of feeding success, and no safety differences between the two treatment groups were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.